217 results
P
Hepatocellular carcinomas (HCCs), non-HCC malignancies
I/C
Contrast-enhanced ultrasound (CEUS) Liver Imaging Reporting and Data System category M (LR-M), CEUS LR-M category, Non-HCC malignancies
O
Proportion of CEUS LR-M in HCC and non-HCC malignancies, Frequency of individual CEUS LR-M imaging features
P
patients with liver lesions
I/C
LI-RADS algorithm, original studies reporting probability of LR-M for HCC and non-HCC malignancy on MRI
O
pooled percentages of HCC and non-HCC malignancy for LR-M, sources of heterogeneity between reported results
P
children
I/C
hormones, AEDs, AEDs alone
O
clinical improvement rate, seizure control, EEG abnormalities, cognition
P
HLA alleles
I/C
Antiepileptic drugs (AEDs), SJS/TEN
O
association between HLA and AED-induced SJS/TEN
P
rodents
I/C
unmodified MSC(M), controls
O
mortality rate
P
HGG patients without a history of seizures
I/C
prophylactic antiepileptic drugs (AED), controls
O
incidence of postoperative seizures
P
HIV-infected adults with tuberculosis
I/C
Mycobacterium tuberculosis bloodstream infection (BSI), Patients with HIV-associated tuberculosis but without M. tuberculosis BSI
O
Mortality within 30 days
P
patients with recurrent or metastatic head and neck squamous cell carcinomas (R/M HNSCC)
I/C
PD-1/PDL-1 inhibitors, anti-EGFR agents, cetuximab, panitumumab, control, platinum-resistant disease, methotrexate, platinum-based regimens
O
overall survival (OS), progression-free survival (PFS), overall response rates (ORR)
P
patients with M. chimaera infection and a prior history of cardiac surgery
I/C
surgical aortic valve replacement or combined aortic valve and root replacement, lethal events
O
better survival
P
neonates
I/C
phenobarbitone, other anti-epileptic drugs (AEDs)
O
seizure control, adverse effects, neurodevelopmental outcomes